Fenwick & West

Slice Emerges from Stealth with $7 Million Seed Funding to Automate Global Equity Management with AI-powered Compliance and Tax Monitor

Retrieved on: 
Wednesday, February 28, 2024
Engineering, AI, TEL, CPO, Risk, CFOS, HR, Weizmann Institute of Science, Salesforce, Fenwick & West, Legalease Ltd., Life insurance

WILMINGTON, Del. and TEL AVIV, Israel, Feb. 28, 2024 /PRNewswire/ -- Slice, the only global equity platform utilizing AI for continuous compliance, announced today it has emerged from stealth with a $7 million seed funding round led by TLV Partners, with participation from R-Squared Ventures, Jibe Ventures, leading international law firms Wilson Sonsini, Fenwick & West and notable angel investors.

Key Points: 
  • Workforces have become truly global , and as the job market becomes more competitive, equity makes up a significant part of the talent compensation package.
  • The AI-powered platform automatically ensures that all global equity operations are compliant and tax-optimized to maximize and protect the benefits of equity plans, both for employers and employees.
  • Slice is the first to apply LLMs to the world of equity compliance, enabling its pre-trained platform to quickly learn and apply country-specific tax codes and regulations that impact equity awards.
  • We firmly believe they will quickly be able to deliver a new standard for global equity management and compliance."

Macrae Strengthens Presence in New York and San Francisco with the Addition of Two Managing Directors

Retrieved on: 
Thursday, January 11, 2024
Professional Services, Legal, Human Resources, Fenwick & West, Diversity, Lawyer, Human resources, University, San Francisco Bay Area, Santa Clara University, University of San Francisco, Organization, Growth

Macrae , a premier transatlantic legal search firm that places partners and partner groups at the world’s leading law firms, has deepened its footprint in New York and San Francisco with the addition of Managing Directors Tad Gruman and Julieta Stubrin .

Key Points: 
  • Macrae , a premier transatlantic legal search firm that places partners and partner groups at the world’s leading law firms, has deepened its footprint in New York and San Francisco with the addition of Managing Directors Tad Gruman and Julieta Stubrin .
  • “We’re thrilled to kick off the new year with Tad and Julieta on board,” said Joe Macrae , Founder and Chairman.
  • Gruman , who joined Macrae from Whistler Partners, has nearly a decade of experience placing lawyers into the leading law firms in New York.
  • Stubrin has more than 20 years of experience matching lawyers with elite firms in the San Francisco Bay Area and beyond.

Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

Retrieved on: 
Thursday, October 5, 2023
Sale, IMPL, Bladelet (impeller), Fenwick & West, Dihydroergotamine

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives.

Key Points: 
  • SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives.
  • As the Company explores strategic options, Impel continues to provide full commercial support behind Trudhesa, including Trudhesa Direct access support.
  • There can be no assurance that this process will result in the Company pursuing or consummating any particular transaction or other strategic outcome.
  • However, if the Company is unable to complete a transaction, it may be necessary to seek additional financing or other alternatives for restructuring and resolving its liabilities.

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Retrieved on: 
Tuesday, September 5, 2023
Fenwick & West, Patient, Southern Transcon, Latham & Watkins, Pediatrics, Fine chemical, Pharmaceutical industry

NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue.

Key Points: 
  • NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue.
  • We are pleased to partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, and look forward to partnering with them in the coming years,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer.
  • The royalty payments to Royalty Pharma will cease upon reaching a multiple of 1.925x, or 1.65x if Royalty Pharma receives royalties in that amount by December 31, 2031.
  • Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal advisors to Royalty Pharma.

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Retrieved on: 
Tuesday, September 5, 2023
Fenwick & West, Patient, Southern Transcon, Latham & Watkins, Pediatrics, Fine chemical, Pharmaceutical industry

COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.

Key Points: 
  • - Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes
    COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.
  • The royalty payments to Royalty Pharma will cease upon reaching a multiple of 1.925x, or 1.65x if Royalty Pharma receives royalties in that amount by December 31, 2031.
  • Evercore acted as financial advisor and Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction.
  • Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal advisors to Royalty Pharma.

Boundless Immigration Acquires Bridge to Transform Immigration for Businesses and Families

Retrieved on: 
Tuesday, August 22, 2023
Professional Services, Technology, Other Professional Services, Legal, Other Technology, Software, Workforce, Interview, H-1B, History, Wang, Acquisition, Inclusion, Growth, Boundless, Fenwick & West, Ecosystem, Clothing, Management, Bridge

Expanding its suite of immigration services, Boundless Immigration announced today its acquisition of Bridge , a startup at the forefront of visa application processes for the global workforce.

Key Points: 
  • Expanding its suite of immigration services, Boundless Immigration announced today its acquisition of Bridge , a startup at the forefront of visa application processes for the global workforce.
  • The merger underscores Boundless’ transformative approach to immigration, uniting business leaders and individual immigrant families to provide a holistic solution to the immigration journey, addressing both corporate immigration strategies and the personal challenges faced by the global workforce and their families.
  • We’re building an ecosystem where immigration processes become immigration strategies for businesses, and now, for families too," said Romish Badani, CEO of Bridge.
  • Strengthen Diversity, Equity, and Inclusion Strategies: Boundless and Bridge can help businesses build a more inclusive workforce, a foundation of diversity that fuels innovation, growth, and employee satisfaction.

The SCHMID GROUP to List on NYSE through Business Combination with Pegasus Digital Mobility Acquisition Corp.

Retrieved on: 
Wednesday, May 31, 2023
Clifford Chance, Appleby, Gebr. Heller, Hans-Christian Schmid, Electronics, Internet of things, Original equipment manufacturer, PGSS, Business analyst, USD, PV, Cyprus Securities and Exchange Commission, Internet, EUR, EBITDA, State, Miniaturization, Acquisition, PCB, Growth, Fenwick & West, Silicon, AI, R, TAM, NYSE, Glass, Economics, Software, Printed circuit board, Video game, Retail, Industrial design, Management, Renewable energy, Cryptocurrency, Pegasus

SCHMID management believes that as the industry's full-service provider of this solution, the company is well positioned to meaningfully outpace strong industry growth.

Key Points: 
  • SCHMID management believes that as the industry's full-service provider of this solution, the company is well positioned to meaningfully outpace strong industry growth.
  • Schmid family to maintain majority ownership and retain management positions post-listing; Board expected to include Christian Schmid and Anette Schmid, Pegasus officers Sir Ralf Speth and Dr. Stefan Berger, and three independent board members.
  • SCHMID GmbH (the "Company" or "SCHMID," and together with its consolidated subsidiaries, the "SCHMID Group" or "Group"), a global solutions provider for the high-tech electronic, photovoltaics, glass, and energy systems industries, and Pegasus Digital Mobility Acquisition Corp. ("Pegasus") (NYSE: PGSS), a special purpose acquisition company formed by StratCap, LLC today announced a definitive business combination agreement (the "Business Combination Agreement") that would result in the SCHMID Group becoming a publicly listed company on the New York Stock Exchange (NYSE), expected in the fourth quarter of 2023.
  • Solomon Partners Securities, LLC is serving as financial advisor to Pegasus Digital Mobility Acquisition Corp. on the transaction.

Orrick Adds Leading Tech Capital Markets Advisor Jamie Evans

Retrieved on: 
Monday, March 13, 2023
Professional Services, Technology, Legal, Other Technology, Finance, Consulting, History, J. P. Morgan, Peloton, Union Street, Fenwick & West, Intelligence, Silicon, Citigroup, Zillow, Initial public offering, Culture, Chambers, Capital market, Multimedia, Goldman Sachs, Chambers and Partners, Fintech, Morgan Stanley, ZipRecruiter, Cryptocurrency, Security (finance), Fitbit, Compass

View the full release here: https://www.businesswire.com/news/home/20230310005290/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230310005290/en/
    Jamie Evans joins Orrick from Fenwick & West, where he co-chaired the Capital Markets & Public Companies Group.
  • Jamie joins an Orrick tech practice that is counsel to over 4,000 emerging growth companies, including over 700 new companies added in 2022, as well as many leading public tech companies.
  • “Jamie has a stellar record in tech capital markets, including having worked on some of tech’s landmark IPOs.
  • His close ties to the tech community and the bankers and other financial advisors who support it will complement our relationships in the tech ecosystem,” said Orrick Chair Mitch Zuklie.

Fishman Haygood Files Most Comprehensive Suit Yet to Recover Funds on Behalf of Victims of FTX Fallout

Retrieved on: 
Thursday, February 23, 2023
Class Action Lawsuit, Professional Services, Legal, SEN, FTX, SoftBank Group, PLLC, Trust, Signature Bank, Sequoia, Signature, LLP, Research, Fenwick & West, Sam Bankman-Fried, Thoma Bravo, Haygood, Bank, Theft, Silvergate, Silvergate Bank, Sequoia Capital, Alameda Research, Sale, Bank Secrecy Act, Cryptocurrency, Fraud

To further assist with Bankman-Fried’s siphoning of customer funds, the suit alleges, the banks developed state-of-the-art blockchain technologies—Silvergate’s SEN and Signature’s Signet platforms—through which FTX could funnel customer funds through Alameda or other shadowy entities and into Bankman-Fried’s pockets.

Key Points: 
  • To further assist with Bankman-Fried’s siphoning of customer funds, the suit alleges, the banks developed state-of-the-art blockchain technologies—Silvergate’s SEN and Signature’s Signet platforms—through which FTX could funnel customer funds through Alameda or other shadowy entities and into Bankman-Fried’s pockets.
  • The suit also alleges that Deltec Bank and Trust, a Bahamian bank with close ties to Bankman-Fried, helped to fence assets from FTX accounts at Silvergate and Signature to Bankman-Fried’s accounts offshore.
  • The case has been allotted to Judge Jose E. Martinez and is currently being served on defendants.
  • A copy of the suit, which contains a full list of the defendants and comprehensive coverage of defendants’ assistance to the Fraud is available here .

Tidepool Announces Appointment of John Lister as New Chief Operating Officer

Retrieved on: 
Tuesday, January 24, 2023
Diabetes, Medical Devices, Health, Technology, Software, Caregiver, University, CGM, Fenwick & West, Dexcom, Patient, IPhone, Pharmaceutical industry, Tide pool

Tidepool, a recognized innovator in the diabetes space driving interoperability for all diabetes software and devices, announced that John Lister, has been appointed to the Tidepool team as Chief Operating Officer.

Key Points: 
  • Tidepool, a recognized innovator in the diabetes space driving interoperability for all diabetes software and devices, announced that John Lister, has been appointed to the Tidepool team as Chief Operating Officer.
  • During his tenure John served on Dexcom’s executive management team, which led the launch of six generations of CGM in over 35 countries.
  • Tidepool is anticipating clearance for Tidepool Loop, an iPhone-controlled interoperable automated glycemic controller (iAGC) for type 1 diabetes management.
  • Tidepool is also filling the gap for unmet clinician needs with Tidepool+, their clinic offering.